McKesson Corp (MCK)

Their hospital information system is easy to use and far better than some other painfully slow systems that I have used.

Demographics play.

Health care reform (and actually part of the stimulus as well) should help this stock get even further ahead as digitization is government funded. It is an industry leader in these services, and will probably see large gains, similar to Quality Systems.

health care leader

navallier:A, moneycentral:9

Tracking this one. Health Care Reform

leading generic drug wholesaler

This company has a stable senior management team, has been on a tear for a while now, and is in a market sector that is growing on a massive scale.

Healthcare overhaul..no brainer

There isn't a lot that I like about MCK, but their technicals are looking pretty solid, largely on Obama healthcare reform I suspect.

Financially, the company is carrying more debt than I like, about 41% Debt/Equity. Their profit margins are razor thin at 0.77%. Their Quick ratio is a bit scary, but their current ratio suggests they have enough cash to hold on through the next 12 months.

I looking for a short-term pop while the market corrects.

excellent dividend and the stock has the potential to be trading in the 38-42 range, which presents an upside of 30 to 40% from the current levels.

People need their drugs.

We're getting older. I like the idea of betting on a solid company like McKesson a lot more than hoping a pharma giant will find some expensive new homerun drugs.

Company is profitable and McKesson has been profitable for a long time and will continue to be so as the baby boom generation increases demand for its products.

The health care distribution sector is likely to continue growing with the aging population. Should national health care become a reality more people will have access to distributors such as Mckesson. They continue to generate and grow their free cash flow (which I believe is the life blood of any company) allowing for internal capital funding in these tight credit times, They have a solid balance sheet which current prices seem to be undervaluing.

Sold growth oriented company with strong financials

MARCH PICK

cheap and still growing revenues - still a demographic play despite healthcare reform.

A giant of the health care industry -- all the analysts seem to love it these days, and it isn't dependent on the success/approval of any particular drug.

I wanted to increase my exposure to the health care sector (which should help lead the way out of this economic crisis). Bought in today on a nice dip.